FindTrial
Sign In

I4V-MC-KHAB: A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516824-32-00
Acronym
I4V-MC-KHAB
Enrollment
4
Registered
2024-09-27
Start date
2021-11-15
Completion date
2025-09-17
Last updated
2025-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19 Corona Virus Infection

Brief summary

Pharmacokinetics (PK): Area Under Concentration Curve (AUC) of Baricitinib, PK: Maximum Concentration (Cmax) of Baricitinib

Interventions

DRUGBaricitinib

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Pharmacokinetics (PK): Area Under Concentration Curve (AUC) of Baricitinib, PK: Maximum Concentration (Cmax) of Baricitinib—

Countries

Belgium, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026